What is IKT's current stock price?

IKT (Inhibikase Therapeutics, Inc.) is currently trading at $1.69 with a market cap of $120.0M.

What sector is Inhibikase Therapeutics, Inc. in?

Inhibikase Therapeutics, Inc. (IKT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IKT a good stock to buy?

Analysts have a Buy consensus on IKT with a price target of $4.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IKT Inhibikase Therapeutics, Inc.

Healthcare

$1.69-2.87%ClosedMarket Cap: $120.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.99

P/S

0.00

EV/EBITDA

-1.26

DCF Value

$1.41

FCF Yield

-30.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-41.3%

ROA

-29.4%

ROIC

-33.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-16.4M	$—
Q4 null	$0.00	$-12.7M	$—
FY null	$0.00	$-48.3M	$—
Q3 null	$0.00	$-11.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$4.00

Target (Median)

$4.00

Target Range

$4.00 - $4.00

1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Munshi Amitdirector

SellTue Feb 24

Cabell Christopherofficer: President & Head of R&D

SellTue Feb 24

Aurentz Vincentdirector

SellTue Feb 24

McIntyre Davidofficer: Chief Financial Officer

SellWed Jan 07

Iwicki Mark Tdirector, officer: Chief Executive Officer

SellWed Jan 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.96

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Peers